AngioDynamics sells dialysis product portfolio and BioSentry to Merit Medical for $100M cash

ANGIODYNAMICS INC

Deal includes DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT, Vaxel Plus catheters and BioSentry biopsy product.
Divested portfolio contributed approximately $32M in sales in FY2023.
Net proceeds will be used to eliminate existing debt and fund strategic growth investments.
Transaction is dilutive to adjusted EPS and slightly dilutive to corporate gross margins.
Preliminary FY2023 net sales in the range of $338M to $339M; full results due early July.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.